Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Abpro Holdings, Inc - Common Stock
(NQ:
ABP
)
5.770
UNCHANGED
Streaming Delayed Price
Updated: 3:51 PM EST, Dec 15, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abpro Holdings, Inc - Common Stock
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
December 15, 2025
From
Abpro Corporation
Via
GlobeNewswire
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
December 09, 2025
Continued listing reflects progress on turnaround strategy and pipeline advancement
From
Abpro Corporation
Via
GlobeNewswire
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
November 04, 2025
From
Abpro Corporation
Via
GlobeNewswire
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
November 03, 2025
From
Abpro Corporation
Via
GlobeNewswire
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
April 27, 2025
From
Abpro Corporation
Via
GlobeNewswire
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
March 25, 2025
Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72
From
Abpro Corporation
Via
GlobeNewswire
Abpro Statement on the Departure of Former CEO Ian Chan
March 10, 2025
From
Abpro Corporation
Via
GlobeNewswire
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing
December 12, 2024
From
Abpro Corporation
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today